Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Stefanie Ruf, Alexander Martin Heberle, Miriam Langelaar-Makkinje, Sara Gelino, Deepti Wilkinson, Carolin Gerbeth, Jennifer Jasmin Schwarz, Birgit Holzwarth, Bettina Warscheid, Chris Meisinger, Marcel A. T. M. van Vugt, Ralf Baumeister, Malene Hansen & Kathrin Thedieck. (2017) PLK1 (polo like kinase 1) inhibits MTOR complex 1 and promotes autophagy. Autophagy 13:3, pages 486-505.
Read now
Read now
Tian Shao & Xiaoqi Liu. (2015) Identification of Rictor as a Novel Substrate of Polo-like kinase 1. Cell Cycle 14:5, pages 755-760.
Read now
Read now
Zeng-Fu Shang, Lan Yu, Bing Li, Wen-Zhi Tu, Yu Wang, Xiao-Dan Liu, Hua Guan, Bo Huang, Wei-Qing Rang & Ping-Kun Zhou. (2012) 4E-BP1 participates in maintaining spindle integrity and genomic stability via interacting with PLK1. Cell Cycle 11:18, pages 3463-3471.
Read now
Read now
Galina Tsykunova, Håkon Reikvam, Aymen Bushra Ahmed, Ina Nepstad, Bjørn Tore Gjertsen & Øystein Bruserud. (2012) Targeting of polo-like kinases and their cross talk with Aurora kinases – possible therapeutic strategies in human acute myeloid leukemia?. Expert Opinion on Investigational Drugs 21:5, pages 587-603.
Read now
Read now
Articles from other publishers (17)
Yaxi Li, Hongting Wang, Zijing Zhang, Chenling Tang, Xinjin Zhou, Chandra Mohan & Tianfu Wu. (2022) Identification of polo‐like kinase 1 as a therapeutic target in murine lupus. Clinical & Translational Immunology 11:1.
Crossref
Crossref
Yong Weon Yi, Kyu Sic You, Jeong-Soo Park, Seok-Geun Lee & Yeon-Sun Seong. (2021) Ribosomal Protein S6: A Potential Therapeutic Target against Cancer?. International Journal of Molecular Sciences 23:1, pages 48.
Crossref
Crossref
Mini Jeong, Mi Hyeon Jeong, Jung Eun Kim, Serin Cho, Kyoung Jin Lee, Serkin Park, Jeongwon Sohn & Yun Gyu Park. (2021) TCTP protein degradation by targeting mTORC1 and signaling through S6K, Akt, and Plk1 sensitizes lung cancer cells to DNA-damaging drugs. Scientific Reports 11:1.
Crossref
Crossref
Alexandria C. Rutkovsky, Elizabeth S. Yeh, Stephen T. Guest, Victoria J. Findlay, Robin C. Muise-Helmericks, Kent Armeson & Stephen P. Ethier. (2019) Eukaryotic initiation factor 4E-binding protein as an oncogene in breast cancer. BMC Cancer 19:1.
Crossref
Crossref
Minqing Jiang, Rohit Rao, Jincheng Wang, Jiajia Wang, Lingli Xu, Lai Man Wu, Jonah R. Chan, Huimin Wang & Q. Richard Lu. (2018) The TSC1-mTOR-PLK axis regulates the homeostatic switch from Schwann cell proliferation to myelination in a stage-specific manner. Glia 66:9, pages 1947-1959.
Crossref
Crossref
Ting-Ting Liu, Kai-Xia Yang, Jing Yu, Ying-Ya Cao, Jian-Song Ren, Jia-Jie Hao, Bei-Qing Pan, Sai Ma, Li-Yan Yang, Yan Cai, Ming-Rong Wang & Yu Zhang. (2018) Co-targeting PLK1 and mTOR induces synergistic inhibitory effects against esophageal squamous cell carcinoma. Journal of Molecular Medicine 96:8, pages 807-817.
Crossref
Crossref
Zhiguo Li, Yifan Kong, Longzhen Song, Qian Luo, Jinghui Liu, Chen Shao, Xianzeng Hou & Xiaoqi Liu. (2018) Plk1-Mediated Phosphorylation of TSC1 Enhances the Efficacy of Rapamycin. Cancer Research 78:11, pages 2864-2875.
Crossref
Crossref
Melpomeni Platani, Itaru Samejima, Kumiko Samejima, Masato T. Kanemaki & W. C. Earnshaw. (2018) Seh1 targets GATOR2 and Nup153 to mitotic chromosomes. Journal of Cell Science.
Crossref
Crossref
Andreas Ritter, Alexandra Friemel, Nina-Naomi Kreis, Frank Louwen & Juping Yuan. (2016) Impact of Polo-like kinase 1 inhibitors on human adipose tissue-derived mesenchymal stem cells. Oncotarget 7:51, pages 84271-84285.
Crossref
Crossref
Chelsea E. Cunningham, Shuangshuang Li, Frederick S. Vizeacoumar, Kalpana Kalyanasundaram Bhanumathy, Joo Sang Lee, Sreejit Parameswaran, Levi Furber, Omar Abuhussein, James M. Paul, Megan McDonald, Shaina D. Templeton, Hersh Shukla, Amr M. El Zawily, Frederick Boyd, Nezeka Alli, Darrell D. Mousseau, Ron Geyer, Keith Bonham, Deborah H. Anderson, Jiong Yan, Li-Yuan Yu-Lee, Beth A. Weaver, Maruti Uppalapati, Eytan Ruppin, Anna Sablina, Andrew Freywald & Franco J. Vizeacoumar. (2016) Therapeutic relevance of the protein phosphatase 2A in cancer. Oncotarget 7:38, pages 61544-61561.
Crossref
Crossref
Melpomeni Platani, Laura Trinkle-Mulcahy, Michael Porter, A. Arockia Jeyaprakash & William C. Earnshaw. (2015) Mio depletion links mTOR regulation to Aurora A and Plk1 activation at mitotic centrosomes. Journal of Cell Biology 210:1, pages 45-62.
Crossref
Crossref
B T Gjertsen & P Schöffski. (2014) Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy. Leukemia 29:1, pages 11-19.
Crossref
Crossref
Min Soo Kim, Gyoung Mi Kim, Yun-Jeong Choi, Hye Joung Kim, Yoo-Jin Kim & Wook Jin. (2013) c-Src activation through a TrkA and c-Src interaction is essential for cell proliferation and hematological malignancies. Biochemical and Biophysical Research Communications 441:2, pages 431-437.
Crossref
Crossref
Min Soo Kim, Gyoung Mi Kim, Yun-Jeong Choi, Hye Joung Kim, Yoo-Jin Kim & Wook Jin. (2013) TrkC promotes survival and growth of leukemia cells through Akt-mTOR-Dependent Up-Regulation of PLK-1 and Twist-1. Molecules and Cells 36:2, pages 177-184.
Crossref
Crossref
Olga V. Leontieva, Geraldine M. Paszkiewicz & Mikhail V. Blagosklonny. (2012) Mechanistic or mammalian target of rapamycin (mTOR) may determine robustness in young male mice at the cost of accelerated aging. Aging 4:12, pages 899-916.
Crossref
Crossref
Bing Song, Korbin Davis, X. Shawn Liu, Hyoung-gon Lee, Mark Smith & Xiaoqi Liu. (2011) Inhibition of Polo-like kinase 1 reduces beta-amyloid-induced neuronal cell death in Alzheimer's disease. Aging 3:9, pages 846-851.
Crossref
Crossref
William H. Chappell, Linda S. Steelman, Jacquelyn M. Long, Ruth C. Kempf, Stephen L. Abrams, Richard A. Franklin, Jörg Bäsecke, Franca Stivala, Marco Donia, Paolo Fagone, Graziella Malaponte, Maria C. Mazzarino, Ferdinando Nicoletti, Massimo Libra, Danijela Maksimovic-Ivanic, Sanja Mijatovic, Giuseppe Montalto, Melchiorre Cervello, Piotr Laidler, Michele Milella, Agostino Tafuri, Antonio Bonati, Camilla Evangelisti, Lucio Cocco, Alberto M. Martelli & James A. McCubrey. (2011) Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health. Oncotarget 2:3, pages 135-164.
Crossref
Crossref